1,2,2-三甲基哌嗪盐酸盐 | 1312784-54-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 中文名称: 1,2,2-三甲基哌嗪盐酸盐
• 英文名称: 1,2,2-trimethylpiperazine dihydrochloride
• 英文别名: 1,2,2-Trimethylpiperazine hydrochloride；1,2,2-trimethylpiperazine;hydrochloride
• CAS: 1312784-54-5
• 化学式: C₇H₁₆N₂*2ClH
• mdl: MFCD09864551
• 分子量: 201.139
• InChiKey: AWYYVHSHGGSKCG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.35
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  15.3
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  1,2,2-三甲基哌嗪盐酸盐 、 对氟硝基苯 在 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 21.0h， 以97%的产率得到1,2,2-trimethyl-4-(4-nitrophenyl)piperazine
  参考文献：
  名称：

  [EN] PYRIMIDOPYRIMIDINONES USEFUL AS WEE-1 KINASE INHIBITORS
  [FR] PYRIMIDOPYRIMIDINONES UTILES COMME INHIBITEURS DE LA WEE-1 KINASE

  摘要：

  本发明涉及一类可用作Wee-1激酶活性抑制剂的化合物。本发明还涉及包含这些化合物的药物组合物以及使用这些化合物治疗癌症的方法和治疗癌症的方法。

  公开号：

  WO2015092431A1

文献信息

• [EN] 3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH<br/>[FR] 3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES COMME INHIBITEURS D'IDH MUTANTE
  申请人：NOVARTIS AG

  公开号：WO2014141104A1

  公开（公告）日：2014-09-18

  The invention is directed to a formula (I), or a pharmamceutically acceptable salt thereof, wherein R1, R2a, R2b and R3-R7 are herein. The invention is also directed to compositions containing a compound of formula (I) and to the use of such compounds in the inhibition of mutant IDH proteins having a neomorphic activity. The invention is further directed to the use of a compound of formula (I) in the treatment of diseases or disorders associated with such mutant IDH proteins including, but not limited to, cell-proliferation disorders, such as cancer.

  这项发明涉及一种式(I)的配方，或其药用可接受的盐，其中R1、R2a、R2b和R3-R7在此处。该发明还涉及含有式(I)化合物的组合物，以及在抑制具有新型活性的突变IDH蛋白中使用这种化合物的用途。该发明还涉及在治疗与这种突变IDH蛋白相关的疾病或紊乱中使用式(I)化合物，包括但不限于细胞增殖紊乱，如癌症。
• 4-Phenyl-6-substituted-pyrimidine-2-carbonitrile derivatives
  申请人：Rankovic Zoran

  公开号：US20070111992A1

  公开（公告）日：2007-05-17

  Disclosed herein are 4-phenyl-6-substituted-pyrimidine-2-carbonitrile derivatives having Formula I, wherein each of the substituents is given the definition as set forth in the specification and claims; or a pharmaceutically acceptable salt thereof. Also disclosed are pharmaceutical compositions comprising these 4-phenyl-6-substituted-pyrimidine-2-carbonitrile derivatives and use of these 4-phenyl-6-substituted-pyrimidine-2-carbonitrile derivatives for the treatment of cathepsin K and cathepsin S related disorders, e.g. osteoporosis, atherosclerosis, inflammation and immune disorders such as rheumatoid arthritis and chronic pain.

  本文披露了具有化学式I的4-苯基-6-取代嘧啶-2-碳腈衍生物，其中每个取代基的定义如规范和索赔中所述；或其药学上可接受的盐。还披露了包含这些4-苯基-6-取代嘧啶-2-碳腈衍生物的药物组合物，以及利用这些4-苯基-6-取代嘧啶-2-碳腈衍生物治疗与卡特普辛K和卡特普辛S相关的疾病，例如骨质疏松症、动脉粥样硬化、炎症和风湿性关节炎、慢性疼痛等。
• NOVEL THIENOPYRROLE COMPOUNDS
  申请人：Wishart Neil

  公开号：US20110152243A1

  公开（公告）日：2011-06-23

  The invention provides a compound of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.

  该发明提供了公式（I）的化合物，包括药用盐、前药、生物活性代谢物、立体异构体和同分异构体，其中变量在此处定义。该发明的化合物可用于治疗免疫和肿瘤疾病。
• [EN] 2-AMINOQUINAZOLINES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF<br/>[FR] 2-AMINOQUINAZOLINES SERVANT D'INHIBITEURS DE LRRK2, COMPOSITIONS PHARMACEUTIQUES ET LEURS UTILISATIONS
  申请人：MERCK SHARP & DOHME

  公开号：WO2022051337A1

  公开（公告）日：2022-03-10

  The present invention is directed to certain 2-aminoquinzaoline derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein R1, R3, R4,X1, and X2 are as defined herein, which are potent inhibitors of LRRK2 kinase and may be useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease and other diseases and disorders described herein. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which LRRK-2 kinase is involved.

  本发明涉及公式（I）所示的某些2-氨基喹唑啉衍生物及其药学上可接受的盐，其中R1、R3、R4、X1和X2的定义如本文所述，这些衍生物是LRRK2激酶的有效抑制剂，可用于治疗或预防LRRK2激酶参与的疾病，例如帕金森病和其他本文所述的疾病和疾病。本发明还涉及包含这些化合物的制药组合物以及在预防或治疗LRRK-2激酶参与的这些疾病中使用这些化合物和组合物。
• Spiroindolinones as DDR1 inhibitors
  申请人：Hoffmann-La Roche Inc.

  公开号：US10618897B2

  公开（公告）日：2020-04-14

  The present invention relates to compounds of formula (I): or pharmaceutically acceptable salts thereof, as well as processes for their manufacture, pharmaceutical compositions comprising them, and their use as medicaments.

  本发明涉及式（I）化合物： 或其药学上可接受的盐类，以及它们的制造工艺、包含它们的药物组合物和它们作为药物的用途。